Moderna ’s stock slides as earnings fall short of estimates

Moderna Inc.’s stock fell 7.5% Thursday after the company’s fourth-quarter earnings fell short of estimates amid a steep decline in sales of its COVID vaccine, Spikevax — which is the company’s sole product to have won regulatory approval. Investors were further disappointed by the Cambridge,…#modernaincs #spikevax #cambridge #arpagaray #latinamerica #kuwait #switzerland #taiwan #garay #moderna
Source: Reuters: Health - Category: Consumer Health News Source Type: news